Company Description
Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism.
The company is developing Telomir 1, an oral small molecule metal ion regulator designed to extend telomere caps; maintain cellular balance; and combat oxidative stress that drives aging and disease progression.
By modulating essential metal ions such as iron, and copper, Telomir-1 helps protect against age-related conditions, including Progeria, a rare genetic disorder that causes rapid aging in children; Wilson’s disease, a genetic disorder leading to toxic copper buildup in the body; and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2021 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Erez Aminov |
Contact Details
Address: 100 SE 2nd Street, Suite 2000 #1009 Miami, Florida 33131 United States | |
| Phone | 786 396 6723 |
| Website | telomirpharma.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001971532 |
| CUSIP Number | 87975F104 |
| ISIN Number | US87975F1049 |
| Employer ID | 87-2606031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Michelle Yanez M.B.A. | Chief Financial Officer |
| Dr. Francis E. O'Donnell Jr., M.D. | Chief Medical Officer and Special Advisor |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 4, 2025 | 10-K | Annual Report |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |